keyword
MENU ▼
Read by QxMD icon Read
search

ovarian cancer cytoreduction

keyword
https://www.readbyqxmd.com/read/27922979/a-comparison-of-thermal-plasma-energy-versus-argon-beam-coagulator-induced-intestinal-injury-after-vaporization-in-a-porcine-model
#1
Edward J Tanner, Erica Dun, Yukio Sonoda, Alexander B Olawaiye, Dennis S Chi
OBJECTIVES: Complete cytoreduction of ovarian cancer often requires excision or ablation of bowel serosa implants. Both argon beam coagulator (ABC) and thermal plasma energy (TPE) (PlasmaJet; PlasmaSurgical, Roswell, Ga) have been used to ablate bowel serosa implants. Our objective was to identify comparable power settings as well as determine the rate of bowel perforation, depth of thermal injury, and extent of inflammatory response with ABC versus TPE in a porcine model. MATERIALS AND METHODS: Nine pigs underwent vaporization of small bowel and colon serosa according to assigned treatment group (TPE vs ABC) and settings (ABC: 30, 50, and 70 W; TPE: Cut 10U, 20U, and 30U and Coagulation 10U, 20U, and 30U)...
December 3, 2016: International Journal of Gynecological Cancer
https://www.readbyqxmd.com/read/27906676/role-of-systematic-lymphadenectomy-as-part-of-primary-debulking-surgery-for-optimally-cytoreduced-advanced-ovarian-cancer-reappraisal-in-the-era-of-radical-surgery
#2
Kyung Jin Eoh, Jung-Yun Lee, Jung Won Yoon, Eun Ji Nam, Sunghoon Kim, Sang-Wun Kim, Young Tae Kim
The prognostic significance of pelvic and para-aortic lymphadenectomy during primary debulking surgery for advanced-stage ovarian cancer remains unclear. This study aimed to evaluate the survival impact of lymph node dissection (LND) in patients treated with optimal cytoreduction for advanced ovarian cancer. Data from 158 consecutive patients with stage IIIC-IV disease who underwent optimal cytoreduction (<1 cm) were obtained via retrospective chart review. Patients were classified into two groups: (1) lymph node sampling (LNS), node count <20; and (2) LND, node count ≥20...
November 29, 2016: Oncotarget
https://www.readbyqxmd.com/read/27896512/cytoreduction-peritonectomy-procedures-combined-with-hyperthermic-intraperitoneal-chemotherapy-hipec-in-advanced-ovarian-cancer-retrospective-italian-multicenter-observational-study-of-511-cases
#3
Angelo Di Giorgio, Pierandrea De Iaco, Michele De Simone, Alfredo Garofalo, Giovanni Scambia, Antonio Daniele Pinna, Giorgio Maria Verdecchia, Luca Ansaloni, Antonio Macrì, Paolo Cappellini, Valerio Ceriani, Giorgio Giorda, Daniele Biacchi, Marco Vaira, Mario Valle, Paolo Sammartino
PURPOSE: The aim of this study was to help with the process of selecting patients with advanced ovarian cancer to undergo cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) by analyzing outcome data at distinct clinical time points reflecting the natural history of the disease. METHODS: In a retrospective Italian multicenter study investigating patients with advanced ovarian cancer who underwent CRS plus HIPEC between 1998 and 2014, we analyzed data for consecutive patients at eight treatment time points: primary debulking surgery (PDS); interval debulking surgery after partial response, after no response, and after a pathologic complete response to neoadjuvant chemotherapy; first recurrence with a progression-free interval >12, <12 months, or >12 months in patients who underwent further chemotherapy before CRS and HIPEC; and patients who underwent two or more CRS procedures and chemotherapy lines before CRS and HIPEC...
November 28, 2016: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/27896508/trends-in-mortality-after-primary-cytoreductive-surgery-for-ovarian-cancer-a-systematic-review-and-metaregression-of-randomized-clinical-trials-and-observational-studies
#4
REVIEW
Violante Di Donato, Evangelos Kontopantelis, Giovanni Aletti, Assunta Casorelli, Ilaria Piacenti, Giorgio Bogani, Francesca Lecce, Pierluigi Benedetti Panici
BACKGROUND: Primary cytoreductive surgery (PDS) followed by platinum-based chemotherapy is the cornerstone of treatment and the absence of residual tumor after PDS is universally considered the most important prognostic factor. The aim of the present analysis was to evaluate trend and predictors of 30-day mortality in patients undergoing primary cytoreduction for ovarian cancer. METHODS: Literature was searched for records reporting 30-day mortality after PDS. All cohorts were rated for quality...
November 28, 2016: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/27896308/small-cell-ovarian-carcinoma-long-term-survival-in-juvenile-case-with-poor-prognostic-features
#5
Lauren Stewart, Ruchi Garg, Rochelle Garcia, Elizabeth Swisher
BACKGROUND: Ovarian small cell carcinoma is a rare, aggressive neoplasm that occurs in young women and has a poor long-term prognosis. Treatment involves surgical resection and chemotherapy. The required radicality of surgery is uncertain, balancing cytoreduction with fertility preservation. Various chemotherapy regimens are utilized due to confusion regarding the neoplasm's lineage. Case We describe an adolescent with small cell carcinoma, hypercalcemic type, stage IA. Surgery included left salpingo-oopherectomy, left pelvic/paraaortic lymphadenectomy, omentectomy and peritoneal biopsies...
November 2016: Gynecologic Oncology Reports
https://www.readbyqxmd.com/read/27892998/overall-survival-following-neoadjuvant-chemotherapy-vs-primary-cytoreductive-surgery-in-women-with-epithelial-ovarian-cancer-analysis-of-the-national-cancer-database
#6
J Alejandro Rauh-Hain, Alexander Melamed, Alexi Wright, Allison Gockley, Joel T Clemmer, John O Schorge, Marcela G Del Carmen, Nancy L Keating
Importance: Uncertainty remains about the relative benefits of primary cytoreductive surgery (PCS) vs neoadjuvant chemotherapy (NACT) for advanced-stage epithelial ovarian cancer (EOC). Objective: To compare overall survival of PCS vs NACT in a large national population of women with advanced-stage EOC. Design, Setting, and Participants: Retrospective cohort study of women with stage IIIC and IV EOC diagnosed between 2003 and 2011 treated at hospitals across the United States reporting to the National Cancer Data Base...
November 17, 2016: JAMA Oncology
https://www.readbyqxmd.com/read/27884789/surgery-for-advanced-epithelial-ovarian-cancer
#7
REVIEW
Neville F Hacker, Archana Rao
Cytoreductive surgery for patients with advanced epithelial ovarian cancer has been practised since the pioneering work of Tom Griffiths in 1975. Further research has demonstrated the prognostic significance of the extent of metastatic disease pre-operatively, and of complete cytoreduction post-operatively. Patients with advanced epithelial ovarian cancer should be referred to high volume cancer units, and managed by multidisciplinary teams. The role of thoracoscopy and resection of intrathoracic disease is presently investigational...
October 20, 2016: Best Practice & Research. Clinical Obstetrics & Gynaecology
https://www.readbyqxmd.com/read/27881011/adjuvant-chemotherapy-with-bevacizumab-i-p-can-prolong-survival-time-of-patients-with-advanced-ovarian-cancer-after-cytoreduction
#8
F DU, P Li, J Chen, Z Gong, C Chi, B Hu, H Chu
Objective To assess whether adjuvant chemotherapy with bevacizumab intraperitoneal (i.p.) is better than adjuvant chemotherapy with bevacizumab intravenous (i.v.) or adjuvant chemotherapy only for patients with advanced ovarian cancer after cytoreduction. Selected patients with advanced ovarian cancer after cytoreduction were divided into three groups depend on their will: adjuvant chemotherapy only; adjuvant chemotherapy combined with bevacizumab intravenous (i.v.); adjuvant chemotherapy combined with bevacizumab intraperitoneal (i...
November 24, 2016: Neoplasma
https://www.readbyqxmd.com/read/27874958/diagnostic-accuracy-of-mdct-in-the-evaluation-of-patients-with-peritoneal-carcinomatosis-from-ovarian-cancer-is-delayed-enhanced-phase-really-effective
#9
E Rodolfino, E Devicienti, M Miccò, A Del Ciello, S E Di Giovanni, M Giuliani, C Conte, B Gui, A L Valentini, L Bonomo
OBJECTIVE: To assess the diagnostic accuracy of delayed enhanced phase in addition to portal enhanced phase in MDCT imaging for depicting peritoneal carcinomatosis (PC) implants in patients with ovarian cancer. PATIENTS AND METHODS: We retrospectively reviewed double-phase, portal enhanced phase (PEP) and delayed enhanced phase (DEP), MDCT-examinations of 40 patients with clinical suspicion of recurrent PC from histopathologically-proven ovarian cancer, previously treated with both cytoreductive surgery and adjuvant/neoadjuvant chemotherapy...
November 2016: European Review for Medical and Pharmacological Sciences
https://www.readbyqxmd.com/read/27872532/presentation-and-management-of-inguinal-lymphadenopathy-in-ovarian-cancer
#10
Shveta Giri, Swati H Shah, Kanika Batra, Anu-Bajracharya, Vandana Jain, Himanshu Shukla, Rupinder Sekhon, Sudhir Rawal
The symptoms in ovarian cancer are often missed leading to dubious diagnosis and staging. Inguinal lymphadenopathy (ILAP) is reported to be rare and occurring via lymphatic or hematogenous route. The paucity of studies on ILAP in ovarian cancer indicates a scope of refining its staging and management. The present study aims to document the presentation and management of ILAP in ovarian cancer, which may also reflect its incidence and mechanism of spread. All patients of ovarian cancer with inguinal lymphadenopathy presenting to our institute from 1 January 2015 to 31 December 2015 were included...
December 2016: Indian Journal of Surgical Oncology
https://www.readbyqxmd.com/read/27870700/patterns-of-recurrence-and-clinical-outcome-of-patients-with-stage-iiic-to-stage-iv-epithelial-ovarian-cancer-in-complete-response-after-primary-debulking-surgery-plus-chemotherapy-or-neoadjuvant-chemotherapy-followed-by-interval-debulking-surgery-an-italian
#11
Angiolo Gadducci, Stefania Cosio, Valentina Zizioli, Sara Notaro, Roberta Tana, Andrea Panattoni, Enrico Sartori
OBJECTIVE: The objective of this retrospective study was to assess the clinical outcome of patients with advanced epithelial ovarian cancer in complete response after primary debulking surgery (PDS) or neoadjuvant chemotherapy followed by interval debulking surgery (IDS]). METHODS: The authors reviewed the hospital records of 384 patients who underwent PDS (n = 322) or IDS (n = 62) and who were in complete response after primary treatment. RESULTS: Optimal (residual disease [RD] < 1 cm) and complete (no gross RD) cytoreduction rates were higher after IDS than after PDS (71...
November 17, 2016: International Journal of Gynecological Cancer
https://www.readbyqxmd.com/read/27865654/surgery-for-recurrent-ovarian-cancer-options-and-limits
#12
REVIEW
J Sehouli, J P Grabowski
Cytoreductive surgery is the backbone of the multimodal therapy in primary ovarian cancer patients. Despite the effect of various tumor biological factors such as grading and histological subtype, the surgical outcome is the most important prognostic factor for both progression free- and overall survival. In contrast, the management of recurrent situation has long remained a subject of an emotional international discussion. To date, only few prospective studies have focused on the effect of surgery in relapsed ovarian cancer...
October 21, 2016: Best Practice & Research. Clinical Obstetrics & Gynaecology
https://www.readbyqxmd.com/read/27861355/expression-of-preoperative-kiss1-gene-in-tumor-tissue-with-epithelial-ovarian-cancer-and-its-prognostic-value
#13
Fang Cao, Liping Chen, Manhua Liu, Weiwei Lin, Jinlong Ji, Jun You, Fenghai Qiao, Hongbin Liu
Our study aimed to elucidate the role of Kisspeptin (KISS1) in tumor tissues of patients with epithelial ovarian cancer (EOC) and investigate the prognostic value of this biomarker.Forty EOC patients and 20 uterine fibroids female patients with healthy ovaries undergoing cytoreductive surgery between January 2010 and January 2014 in our hospital were enrolled in this study. KISS1 expression in tumor and normal tissues was detected. Correlations between clinic-pathologic variables and KISS1 expression in EOC tissues and the prognostic value of KISS1 for overall survival were evaluated...
November 2016: Medicine (Baltimore)
https://www.readbyqxmd.com/read/27860146/incidence-of-lymph-node-metastases-in-clinical-early-stage-mucinous-and-seromucinous-ovarian-carcinoma-a-retrospective-cohort-study
#14
Joam van Baal, K K Van de Vijver, S B Coffelt, V van der Noort, W J van Driel, G G Kenter, M R Buist, Car Lok
OBJECTIVE: The use of lymph node sampling during staging procedures in clinical early-stage mucinous ovarian carcinoma (MOC) is an ongoing matter of debate. Furthermore, the incidence of lymph node metastases (LNM) in MOC in relation to tumour grade (G) is unknown. We aimed to determine the incidence of LNM in clinical early-stage MOC per tumour grade. DESIGN: Retrospective study with data from the Dutch Pathology Registry (PALGA). SETTING: The Netherlands, 2002-2012...
November 16, 2016: BJOG: An International Journal of Obstetrics and Gynaecology
https://www.readbyqxmd.com/read/27855557/201-consecutive-cytoreductive-surgery-crs-and-hyperthermic-intraperitoneal-chemotherapy-hipec-procedures-in-a-single-asian-tertiary-centre
#15
Grace Tan, Claramae Chia, Mrinal Kumar, Su Pin Choo, John Chia, Chee Kian Tham, Khee Chee Soo, Melissa Teo
INTRODUCTION: Peritoneal carcinomatosis (PC) is increasingly being treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). We provide a review of a high-volume Asian institute's experience and survival outcomes with this procedure. METHODS: Data was prospectively collected from 201 consecutive CRS and HIPEC procedures performed in a single institution between April 2001 and November 2015. Our primary endpoints were OS and DFS, and secondary endpoints were morbidity and mortality...
November 17, 2016: International Journal of Hyperthermia
https://www.readbyqxmd.com/read/27836207/primary-debulking-surgery-of-the-upper-abdomen-and-the-diaphragm-with-a-plasma-device-surgery-system-for-advanced-ovarian-cancer
#16
Gloria Cordeiro Vidal, Guillaume Babin, Denis Querleu, Frédéric Guyon
OBJECTIVE: Electrically neutral argon plasma (PlasmaJet™) technology is a surgical option that helps to get an aggressive cytoreduction in selected patients with ovarian cancer because it can be directly applied by the surgeon to treat the tissue surface [1,2]. Upper abdominal surgical procedures are an important part of the surgery in these patients [3], there is a 22% complications rate when they are performed [4]. We present a surgical approach to ovarian cancer debulking using PlasmaJet™...
November 8, 2016: Gynecologic Oncology
https://www.readbyqxmd.com/read/27836206/the-effect-of-polymorphisms-in-pd-1-gene-on-the-risk-of-epithelial-ovarian-cancer-and-patients-outcomes
#17
Yan Li, Hui-Lan Zhang, Shan Kang, Rong-Miao Zhou, Na Wang
OBJECTIVE: Programmed death-1 (PD-1), an important immunosuppressive molecule, plays a key role in tumor-cell-mediated immune escape. In the present study, we evaluated the effect of PD-1 gene polymorphisms on the risk of developing epithelial ovarian cancer (EOC) and patients' outcomes. METHODS: A case-control study was performed in 620 EOC patients and 620 control women. Survival data were available for 258 patients who received platinum-based chemotherapy after cytoreductive surgery...
November 8, 2016: Gynecologic Oncology
https://www.readbyqxmd.com/read/27833898/nuak1-ark5-is-associated-with-poor-prognosis-in-ovarian-cancer
#18
Neil T Phippen, Nicholas W Bateman, Guisong Wang, Kelly A Conrads, Wei Ao, Pang-Ning Teng, Tracy A Litzi, Julie Oliver, G Larry Maxwell, Chad A Hamilton, Kathleen M Darcy, Thomas P Conrads
BACKGROUND AND OBJECTIVE: Nua kinase 1 (NUAK1) was identified in multigene signatures of survival and suboptimal debulking in high-grade serous ovarian cancer (HGSOC). This study investigates the individual clinical and biologic contributions of NUAK1 in HGSOC patients and cell lines. METHODS: Public transcript expression, clinical, and outcome data were used to interrogate the relationship between NUAK1 and clinicopathologic factors and patient outcomes including progression-free survival (PFS) and molecular subtypes using logistic and Cox modeling...
2016: Frontiers in Oncology
https://www.readbyqxmd.com/read/27828713/the-rise-of-genomic-profiling-in-ovarian-cancer
#19
Rebecca A Previs, Anil K Sood, Gordon B Mills, Shannon N Westin
Next-generation sequencing and advances in 'omics technology have rapidly increased our understanding of the molecular landscape of epithelial ovarian cancers. Areas covered: Once characterized only by histologic appearance and clinical behavior, we now understand many of the molecular phenotypes that underlie the different ovarian cancer subtypes. While the current approach to treatment involves standard cytotoxic therapies after cytoreductive surgery for all ovarian cancers regardless of histologic or molecular characteristics, focus has shifted beyond a 'one size fits all' approach to ovarian cancer...
November 9, 2016: Expert Review of Molecular Diagnostics
https://www.readbyqxmd.com/read/27804983/neoadjuvant-chemotherapy-for-patients-with-advanced-epithelial-ovarian-cancer-a-meta-analysis
#20
Long-Jia Zeng, Chun-Lin Xiang, Yi-Zhen Gong, Yan Kuang, Fang-Fang Lu, Su-Yi Yi, Yue Zhang, Meng Liao
The value of neoadjuvant chemotherapy (NAC) has not yet been fully defined. We aimed to systematically evaluate the influence of neoadjuvant chemotherapy (NAC) on survival and complete cytoreduction after debulking surgery in advanced epithelial ovarian cancer (AEOC) patients. We searched PubMed, Embase, and the Cochrane Central Register of Controlled Trials for the randomized controlled trials (RCTs) comparing NAC and primary debulking surgery (PDS) in AEOC patients. The last search date is February 25, 2016...
November 2, 2016: Scientific Reports
keyword
keyword
111476
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"